Mirum falls despite meeting primary goal in phase 3 brelovitug study for hepatitis D
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is set to unveil the results of its Phase 3 AZURE-1 study on brelovitug for chronic hepatitis delta virus on Monday morning. The company will also share data from the Phase 2b stage of the study. Brelovitug, a fully human monoclonal antibody, is in late-stage development for treating chronic hepatitis delta virus.
To participate in the conference call, U.S. callers should dial +1 833 461 5787, while international participants can use +1 585 542 9983, using access code 979912911. A webcast of the call will be available on Mirum's Investors section, with archived replay access post-call. Mirum Pharmaceuticals specializes in rare liver and genetic diseases, with its product portfolio including LIVMARLI, ATEBRIOZ, CHOLBAM, and CTEXLI.
The company's pipeline also includes volixibat and MRM-3379, which are in late-stage development for primary sclerosing cholangitis, primary biliary cholangitis, and Fragile X syndrome, respectively.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Mirum reports Phase 3 victory for acquired hepatitis D med endpoints.news
- Mirum to present phase 3 hepatitis delta study results Monday investing.com
